Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Diwakar Davar
- Target Recruit Count
- 59
- Registration Number
- NCT00972933
- Locations
- ๐บ๐ธ
University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Study of Immunotherapy to Treat Advanced Prostate Cancer
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 988
- Registration Number
- NCT00861614
- Locations
- ๐บ๐ธ
Southern Cancer Center, Mobile, Alabama, United States
๐บ๐ธArizona Clinical Research Center, Inc., Tucson, Arizona, United States
๐บ๐ธLoma Linda University Cancer Center, Loma Linda, California, United States
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2020-02-24
- Target Recruit Count
- 30
- Registration Number
- NCT00836407
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00803374
- Locations
- ๐บ๐ธ
Local Institution, New York, New York, United States
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 72
- Registration Number
- NCT00796991
- Locations
- ๐บ๐ธ
The Angeles Clinic & Research Inst., Los Angeles, California, United States
๐บ๐ธH Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
๐บ๐ธBlumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1211
- Registration Number
- NCT00636168
- Locations
- ๐บ๐ธ
Sharp Memorial Hospital, San Diego, California, United States
๐บ๐ธVanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
๐บ๐ธThe Angeles Clinic & Research Institute, Los Angeles, California, United States
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 99
- Registration Number
- NCT00623766
- Locations
- ๐บ๐ธ
The Angeles Clinic & Research Institute, Los Angeles, California, United States
๐บ๐ธLoyola University Medical Center, Maywood, Illinois, United States
๐บ๐ธSeattle Cancer Care Alliance, Seattle, Washington, United States
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
- Conditions
- Interventions
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT00586391
- Locations
- ๐บ๐ธ
Houston Methodist Hospital, Houston, Texas, United States
๐บ๐ธTexas Children's Hospital, Houston, Texas, United States
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 334
- Registration Number
- NCT00527735
- Locations
- ๐บ๐ธ
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
๐บ๐ธCompassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
๐บ๐ฆLocal Institution, Uzhgorod, Ukraine
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00495066
- Locations
- ๐ง๐ท
Instituto รTICA - AMO - Assistรชncia Multidisciplinar em Oncologia, Salvador, Bahia, Brazil
๐ง๐ทHospital Sao Jose - Beneficencia Portuguesa - Oncology Center, Sao Paulo, SP, Brazil
๐ง๐ทInstituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.